Duquesnoy Publications On HLA Epitopes


This updated list of HLA epitope related publications has been arranged in two sections:

  1. Publications by Rene Duquesnoy at the University of Pittsburgh Medical Center. Clicking on PDF provides access
  2. Publications by other investigators. The large number of references have been sorted in three groups
    • HLAMatchmaker and Eplet-Related Clinical Transplantation Studies
    • HLAMatchmaker Based Platelet Transfusion Reports
    • Antibody Verifications of Eplets, HLA Epitope Structure and Opinions
1. Duquesnoy, RJ: HLAMatchmaker: A Molecularly Based Donor-Selection Algorithm for Highly Allosensitized Patients. Transplantation Proc. 33: 493-497, 2001
2. Duquesnoy, RJ: HLAMatchmaker: A Molecularly Based Algorithm For Histocompatibility Determination I Description of the Algorithm, Human Immunology 63: 339-352, 2002
3. Duquesnoy, RJ and Marrari, M: HLAMatchmaker: A Molecularly Based Algorithm For Histocompatibility Determination II Verification of the Algorithm and Determination of the Relative Immunogenicity of Amino Acid Triplet-Defined Epitopes, Human Immunology 63: 353-263, 2002
4. Duquesnoy, RJ, HLAMatchmaker: A Molecularly Based Algorithm For Histocompatibility Determination. ASHI Quarterly, 2002: p. 60-62
5. Duquesnoy, RJ , Takemoto S, de LangeP, Doxiadis IIN, Schreuder GMTh , Persijn, G and Claas FJH: HLAMatchmaker: A Molecularly Based Algorithm For Histocompatibility Determination III Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival. Transplantation 75: 884-889, 2003
6. Duquesnoy, RJ, Howe J, and Takemoto, S: HLAMatchmaker: A Molecularly Based Algorithm For Histocompatibility Determination. IV An Alternative Strategy to Increase the Number of Compatible Donors for Highly Sensitized Patients, Transplantation 75: 889-897, 2003
7. Duquesnoy, RJ, Witvliet M, Doxiadis I IN, de Fijter H and Claas FHJ: HLAMatchmaker-Based Strategy to Identify Acceptable HLA Class I Mismatches for Highly Sensitized Kidney Transplant Candidates, Transplant International 7: 31-38, 2004
8. Adeyi OE, Girnita A, Howe J, Marrari M, Awadalla Y, Askar M, Martell J, Zeevi A, Shapiro R, Nalesnik M, Rhandawa P, Demetris AJ, and Duquesnoy RJ: Serum Analysis After Kidney Transplant Nephrectomy Reveals Restricted Antibody Specificity Patterns Against Structural HLA Class I Mismatches, Transplant Immunology 14: 53-62, 2005
9. Duquesnoy, RJ and Claas, FHJ: Is the Application of HLAMatchmaker Relevant in Kidney Transplantation? (Letter to the Editor), Transplantation 79: 250-251, 2005
10. Duquesnoy RJ, Mulder A, Askar M, Fernandez-Vina M, and Claas FHJ: HLAMatchmaker-Based Analysis of Human Monoclonal Antibody Reactivity Demonstrates the Importance of an Additional Contact Site for Specific Recognition of Triplet-Defined Epitopes, Human Immunology 66: 749-761, 2005
11. Zeevi A, Girnita A, and Duquesnoy R: HLA antibody analysis: sensitivity, specificity and clinical significance in solid organ transplantation. Immunol. Res. 36:255-64, 2006

12. Duquesnoy RJ: The HLA system and histocompatibility testing for organ transplantation. In Pediatric Transplantation (Eds. Fine R, Webber S, Harmon W, Kelly D and Olthoff K) 2nd Edit (Blackwell Publishing, NY) In Press, 2006
13. Duquesnoy RJ: A structurally based approach to determine HLA compatibility at the humoral immune level. Human immunology 67: 847-862, 2006
14. Duquesnoy, RJ and Claas FHJ: Progress Report of 14th International Histocompatibility Workshop Project on the Structural Basis of HLA Compatibility, Tissue Antigens 69 (Suppl. 1): 1-5, 2007
15. Duquesnoy, RJ and Askar, M: HLAMatchmaker: A Molecularly Based Algorithm for Histocompatibility Determination. V. Eplet Matching for HLA-DR, HLA-DQ and HLA-DP, Human immunology 68: 12-25, 2007
16. Duquesnoy, RJ: “Match and Treat”, An Effective Strategy for Transplanting Highly Sensitized Pediatric Transplant Candidates? (Invited Editorial), Pediatric Transplantation 11: 3-4, 2007
17. Duquesnoy, RJ : Structural Epitope Matching for HLA Alloimmunized Thrombocytopenic Patients: A New Strategy to Provide More Effective Platelet Transfusion Support? Transfusion 48: 221-227, 2008
18. Duquesnoy RJ, Awadalla Y, Lomago J, Jelinek L, Howe J, Zern D, Hunter B, Martell J, Girnita A and A Zeevi: Retransplant Candidates Have Donor-Specific Antibodies that React with Structurally Defined HLA-DR,DQ,DP Epitopes. Transplant Immunology 18: 352-360, 2008
19. Duquesnoy, RJ : Update on HLAMatchmaker: a Molecularly Based Algorithm for Histocompatibility Determination at the Epitope Level, EFI Newsletter, Fall 2007 and ASHI Quarterly 2007: p.74-79
20. Duquesnoy RJ, Spellman S, Haagenson M, Wang T, Horowitz M and Oudshoorn M: HLAMatchmaker-Defined Triplet Matching Is Not Associated with Better Survival Rates of Patients with Class I HLA Allele Mismatched Hematopoietic Cell Transplants from Unrelated Donors. Biol. Blood & Marrow Transplantation 14:1064-1071, 2008
21. Duquesnoy RJ: HLA Class II Antibodies and Transplant Outcome (Invited Analysis and Commentary), Transplantation 86:638-640, 2008
22. Duquesnoy, RJ: Clinical Usefulness of HLAMatchmaker in HLA Epitope Matching for Organ Transplantation, Curr Opinion Immunol. (FJH Claas and RJ Duquesnoy, Eds), 20:1-8 , 2008
23. Duquesnoy RJ, Mostecki J, Hariharan J, and Balasz I: A Structurally Based Epitope Analysis of MICA Antibody Specificity Patterns. Human Immunol. 69: 826-832, 2008
24. Marrari, M and Duquesnoy, RJ: Why can Sensitization by a HLA-DR2 Mismatch lead to Antibodies that react also with HLA-DR1? Human Immunol. 70: 403-9, 2009
25. Duquesnoy RJ and Marrari M: Correlations between Terasaki’s HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A,B and -C antigens, Tissue Antigens 74: 117-133, 2009
26. Marrari M and Duquesnoy, RJ: Correlations between Terasaki’s HLA class II epitopes and HLAMatchmaker-defined eplets on HLADR and DQ antigens, Tissue Antigens 74: 134-146, 2009
27. Duquesnoy RJ and Marrari M: HLAMatchmaker-Based Definition of Structural HLA Epitopes Detected by Alloantibodies, Curr Opinion in Transplantation 14:403-9, 2009
28. Marrari M and Duquesnoy RJ: Detection of donor-specific HLA antibodies in kidney transplant patients before and after removal of a rejected kidney transplant, Transplant Immunology, 22: 105-109, 2010
29. Lomago J, Jelenik l, Zern D, Howe I, Martell J, Zeevi A and Duquesnoy RJ: How did a Patient Who Types for HLA-B*4403 Develop Antibodies that React with HLA-B*4402? Human immunology, 71: 176-178, 2010
30. Marrari M, Mostecki J, Mulder A, Claas F, Balazs and Duquesnoy RJ: Human Monoclonal Antibody Reactivity with HLA Class I Epitopes Defined by Pairs of Human Monoclonal Antibody Reactivity with HLA Class I Epitopes Defined by Pairs of Mismatched Eplets and Self Eplets, Transplantation 90: 1468-72, 2010
31. Duquesnoy RJ and Marrari M: Detection of Antibodies against HLA-C Epitopes in Patients with Rejected Kidney Transplants, Transplant Immunol 24: 164-71, 2011
32. Duquesnoy RJ: Antibody-Reactive Epitope Determination with HLAMatchmaker and Its Application in Transplantation (Invited review), Tissue Antigens 77: 525-534, 2011
33. Duquesnoy RJ: The antibody response to an HLA mismatch: a model for nonself-self discrimination in relation to HLA epitope immunogenicity (Invited Article), Int J Immunogenetics, 39:1-9, 2011
34. Marrari M, Conca R, Praticò-Barbato L, Amoroso A and Duquesnoy: RJ: Brief Report: Why did two patients who type for HLA-B13 have antibodies that react with all Bw4 antigens except HLA-B13? Transplant Immunology, 25: 217-220, 2011
35. Duquesnoy RJ: Humoral Alloimmunity in Transplantation: Relevance of HLA Epitope Antigenicity and Immunogenicity, Frontiers in Transplantation and Alloimmunity, 2: 59, 2011 published online
36. Zeevi A, Marrari M, Feingold B, Webber S and Duquesnoy RJ: HLA epitope analysis to assess complement and non-complement binding donor specific antibody repertoire in a pediatric heart transplant recipient, Hum Immunol, 73: 48-51, 2012
37. Duquesnoy RJ, Marrari M, Mulder A, Claas FJH, Mostecki J and Balazs I: Structural Aspects of HLA Class I Epitopes Detected by Human Monoclonal Antibodies, Human Immunol. 73: 267-277, 2012
38. Duquesnoy RJ, Marrari M, da M. Sousa LCD, de M. Barroso JRP, de SE Aita KM, da Silva AS and do Monte SJH : 16th IHIW: a website for the antibody-defined HLA epitope registry. Int J. Immunogenetics, 40: 54-59, 2013
39. Duquesnoy RJ, Marrari M, Jelenik L, Zeevi A, Claas FHJ and Mulder A: Structural Aspects of HLA Class I Epitopes Reacting with Human Monoclonal Antibodies in Ig-Binding, C1q-Binding and Lymphocytotoxicity Assays, Human Immunology, 74:1271-1279, 2013
40. Duquesnoy RJ: HLA Epitope Based Matching for Transplantation. (Editorial) Transplant Immunology, 31:1-6, 2014
41. Duquesnoy RJ: Update of the HLA Class I Eplet Database in the Website Based Registry of Antibody-Defined HLA Epitopes, Tissue Antigens, 83:382-390, 2014
42. Duquesnoy RJ, Marrari M, Mulder A, da M. Sousa LCD, Da Silva AS, do Monte SJH.: First Report on the Antibody Verification of HLA-ABC Epitopes Recorded in the HLA Epitope Registry. Tissue Antigens 83: 391-400, 2014
43. Duquesnoy RJ, Marrari M, Tambur A, da Mata Sousa LCD, Da Silva AS, do Monte SJH. First Report on the Antibody Verification of HLA-DR, HLA-DQ and HLA-DP Epitopes Recorded in the HLA Epitope Registry. Human Immunology 75:1097-1103, 2014
44. Duquesnoy RJ: HLA epitope based matching for transplantation: the way to go! Terasaki Festschrift, Clinical Transplants 2013, Chapter 53, 441-451, 2014
45. Duquesnoy RJ, Marrari M, Mostecki J, Da Silva AS, da Mata Sousa LCD, do Monte SJH. First Report on the Antibody Verification of MICA Epitopes Recorded in the HLA Epitope Registry, Int J Immunogenetics, 41:370-377, 2014
46. Duquesnoy RJ: Epitope based human leukocyte matching in transplantation(Editorial), Curr Opin Organ Transplantation,19,418-419 , 2014
47. Duquesnoy RJ: HLA Epitope Antigenicity and Immunogenicity, Curr Opin Organ Transplantation, 19, 428-435, 2014
48. Duquesnoy RJ: HLA epitopes and tolerance induction protocols, (Letter to the Editor) Amer J Transplantation, 14:2667, 2014
49. Duquesnoy RJ, Kamoun M, Baxter-Lowe LA, Woodle ES, Bray RA, Claas FHJ, Eckels DD, Friedewald JJ, Fuggle SV, Gebel HM,. Gerlach JA, Fung JJ, Middleton D, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A:Personal Viewpoint: Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High-Resolution rather than the Antigen Level? Am J Transplant. 15: 923-930, 2015
50. Duquesnoy RJ, Gebel HM, Woodle ES, Nickerson P, Baxter-Lowe LA, Bray RA, Claas. FHJ, Eckels DD, Friedewald JJ, Fuggle SV, Gerlach JA, Fung JJ, Kamoun M, Middleton D, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A: High-Resolution HLA Typing for Sensitized Patients: Advances in Medicine and Science Require Us to Challenge Existing Paradigms, (Letter to the Editor) Am J Transplant, 2015
51. Duquesnoy RJ, Marrari M, Mulder A: Usefulness of the nonself-self algorithm of HLA epitope immunogenicity in the specificity analysis of monospecific antibodies induced during pregnancy, Frontiers in Immunology, Vol 6, May 2015
53. Duquesnoy, RJ: The Antibody Response to a HLA Mismatch: Putting Together the Pieces of a Puzzle (editorial) Am J Transplantation,15:3019-20, 2015
54. Duquesnoy RJ, Hönger G, Hösli I, Marrari M and Schaub S: Detection of newly antibody-defined epitopes on HLA class I alleles reacting with antibodies induced during pregnancy. Int J Immunogenetics un 16. doi: 10.1111/iji.12280. [Epub ahead of print], 2016
55. Duquesnoy RJ, Honger G, Hosli I, Marrari M, Schaub S. Identification of epitopes on HLA-DRB alleles reacting with antibodies in sera from women sensitized during pregnancy. Hum Immunol. 77: 214-222, 2016
56. Duquesnoy RJ, Hönger G, Hösli I, Marrari M and Schaub S: Detection : Antibody-defined epitopes on HLA-DQ alleles reacting with antibodies induced during pregnancy and the design of a DQ epitope map, Human Immunology 77: 824-831, 2016
57. Duquesnoy R: The eplet load concept in clinical transplantation, 38:(Invited Editorial) Pediatric Transplantation,20:884-5, 2016
58. Duquesnoy RJ: Should epitope-based compatibility be used in the Kidney Allocation System? Human Immunol, 78: 24-29, 2017
59. Duquesnoy RJ: Reflections on HLA Epitope-Based Matching for Transplantation, Frontiers in Immunology, DOI.org, Nov 28, 2016
60.1 Duquesnoy RJ and Marrari, M: Technology Reports: Application of HLA Epitope-Based Matching in the Clinical Transplant Setting. Part I: Antibody Reactivity with Epitopes ASHI Quarterly and EFI Newsletter, 2016
60.2 Duquesnoy RJ and Marrari, M: Technology Reports: Application of HLA Epitope-Based Matching in the Clinical Transplant Setting. Part II: Pre-Transplant Serum Analysis for Epitope-Specific Antibodies ASHI Quarterly and EFI Newsletter, 2016
60.3 Duquesnoy RJ and Marrari, M: Technology Reports: Application of HLA Epitope-Based Matching in the Clinical Transplant Setting. Part III: Control of Antibody Responses to HLA Epitopes ASHI Quarterly and EFI Newsletter, 2016
61. Duquesnoy RJ: Are we ready for Epitope-Based HLA Matching in Clinical Organ Transplantation? Invited Overview, Transplantation, 101:1755-1765, 2017
62. Duquesnoy RJ and Marrari, M: Usefulness of the ElliPro Epitope Predictor Program in Defining the Repertoire of HLA-ABC Eplets. Human Immunology 78:481-488, 2017
63. Duquesnoy RJ: Epitope-based HLA Matching for Transplantation: A Personal Perspective of Its Future (invited review), Curr Opin Organ Transplant 23: 488-492, 2018
64. Duquesnoy, RJ: The Holy Grail to Clinical Transplant Tolerance is Paved with HLA Epitopes. OBM Transplantation 2, issue 3 doi:10.21926/obm.transplant.1803018, 2018
65. Duquesnoy, R.J., Marrari, M., Marroquin, M.S., Borges, A.G. , da Mata Sousa, L. C. D. , Socorro, A. ,do Monte, S. J. H.: Second update of the International Registry of HLA Epitopes. I. The HLA-ABC epitope database, Hum Immunol doi: 10.1016/j.humimm.2018.11.007
66. Duquesnoy RJ and Marrari M: Interlocus HLA Class II Cross-reactivity: Design of a Repertoire of Eplets Shared between HLA-DR, -DQ and -DP Alleles Rejected by Human Immunology, September 2019

Publications by Other Investigators

HLAMatchmaker and Eplet-Related Clinical Transplantation Studies

  1. Dankers MKA, Witvliet MD, Roelen DL, de Lange P, Korfage N, Persijn GG, Duquesnoy RJ, Doxiadis IIN and Claas FHJ: The Number of Amino Acid Triplet Differences between Patient and Donor is Predictive for the Antibody Reactivity Against Mismatched HLA Antigens, Transplantation I28: 1236-1239, 2004
  2. Laux G, Mansmann U, Deufel A, et al. A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation 2003; 75:1527–1532
  3. Claas FHJ, Witvliet MD, Duquesnoy RJ, Persijn GG and Doxiadis IIN: The Acceptable Mismatch Program as a Fast Tool to Transplant Highly Sensitised Patients Awaiting a Post-Mortal Kidney: Short Waiting Time and Excellent Graft Outcome Transplantation 78: 190-193, 2004
  4. Boehringer D, Reinhard T, Duquesnoy R , Boehringer S, Enczmann J, de Lange P, Claas F, and Sundmacher R : Beneficial Effect of Matching at the HLA-A and B Amino-Acid Triplet Level on Rejection Free Survival in Penetrating Keratoplasty, Transplantation 77: 417-421, 2004
  5. Iniotaki-Theodoraki A, Kalogeropoulou E, Apostolaki M, Doxiadis I, and Stavropoulos-Giokas C: Humoral sensitization against rejected grafts: Specific antibodies to graft immunogenic amino acid triplets. Transplant Proc. 36: 1728-1731, 2004
  6. Lobashevsky, AL, Senkbeil RW, Shoaf JL, Stephenson AK, Skelton SB, Burke RM, Deierhoi MH, and Thomas JM: The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in high PRA renal patients. Human Immunology 63: 364-74, 2002
  7. Varnavidou-Nicolaidou, A, Doxiadis I, Iniotaki-Theodoraki A, Patargias T, Stavropoulos-Giokas C, and Kyriakides G: HLA class I donor-specific triplet antibodies detected after renal transplantation. Transplantation Proceedings 36: 1732-1734, 2004
  8. Laux, G, Mytilineos J, and Opelz G: Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplanation. Transplantation 77: 902-907, 2004
  9. Takemoto S, Port FK, Claas FHJ and Duquesnoy RJ: HLA Matching for Kidney Transplantation, Human Immunology 65: 1489-1505, 2004
  10. Claas FHJ, Dankers MK, Oudshoorn M, van Rood JJ, Mulder A, Roelen DJ, Duquesnoy RJ and Doxiadis IIN: Differential Immunogenicity of HLA Mismatches in Clinical Transplantation. Transplant Immunology 14: 187-191, 2005
  11. Doxiadis IIN, Duquesnoy, RJ, and Claas, FHJ: Extending options for highly sensitized patients to receive a suitable kidney graft. Curr. Opin. Immunol. 17: 536-540, 2005
  12. Haririan A, Fagoaga O, Daneshvar H, Morawski K, Sillix D, El-Amm J, West M, Garnick J, Migdal S, Gruber S, and Nehlsen-Cannarella S: Predictive value of HLA epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort. Clinical Transplantation 20: 226-233 2006
  13. Rosenberg, J, Berri R, Jackowski M, Levis D, Nehlsen-Cannarella S, and Oh H: Multi-array antibody screening in detecting antibodies to mismatched HLA in patients awaiting a second transplant. Transplantation Proceedings 38: 3393-3395, 2006
  14. Mihaylova, A, Baltadjieva D, Boneva P, Ivanova M, Penkova K, Marinova D, Mihailova S, Paskalev E, Simeonov P, and Naumova E: Clinical Relevance of Anti-HLA Antibodies Detected by Flow-Cytometry Bead-Based Assays—Single-Center Experience. Human Immunology 67: 787–794, 2006
  15. Tambur AR, Buckingham M, McDonald L, Luo X. Development of donor-specific and non-donor-specific HLA-DP antibodies post-transplant: the role of epitope sharing and epitope matching. Clinical Transplants. 2006:399-404.
  16. Goodman, RS, Taylor C, O’Rourke C, Lynch A, Bradley JA, and Key T: Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitised patients awaiting kidney transplantation. Transplantation 81: 1331-1336, 2006
  17. Valentini, RP, Nehlsen-Cannarella SL, Gruber SA, Mattoo TK, West MS, Lang C, Imam AA: Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate suucessful transplantation in highly sensitized pediatric renal allograft recipients. Pediatr. Transplant. 11: 77-81, 2007
  18. Smita Vaidya, Brant Hilson, Susan Sheldon, Pedro Cano, Marcelo Fernandez-Vina: DP reactive antibody in a zero mismatch renal transplant pair. Human Immunol 68: 947-949, 2007
  19. Claas FHJ, Doxiadis IIN. Human leukocyte antigen antibody detection and kidney allocation within Eurotransplant. Human Immunology. 2009;70(8):636-9.
  20. Barabanova Y, Ramon D, Tambur AR. Antibodies against HLA-DQ alpha-chain and their role in organ transplantation. Hum Immunol. 2009;70:410-8.
  21. Claas FHJ, Rahmel A, Doxiadis IIN. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation. 2009;88(4):447-52.
  22. Claas FHJ. Towards selective HLA mismatching in clinical transplantation. Transplantation. 2009;88(6):760-1.
  23. Thaunat O, Hanf W, Dubois V, McGregor B, Perrat G, Chauvet C, et al. Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. Transplant Immunology. 2009;20(4):209-11.
  24. Cox ST, Stephens HAF, Fernando R, Karasu A, Harber M, Howie AJ, et al. Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation. Human Immunology. 2011;72(10):827-34.
  25. Cox ST. The relevance and impact of MICA allele mismatching and MICA antibodies on renal transplantation outcome: University College London (UCL); 2011.
  26. Böhringer D, Daub F, Schwartzkopff J, Maier P, Birnbaum F, Sundmacher R and Reinhard T: Operational post-keratopasty graft tolerance due to differential HLAMatchmaker matching. Molecular Vision 16: 2362-2367, 2010
  27. Silva E, Alba A, Castro A, Carrascal M, Buckel E, Aguiló J, Herzog C, Calabrán L, Morales J and Fierro JA: Evaluation of HLAMatchmaker compatibility as predictor of graft survival and presence of anti-HLA antibodies. Transplantation Proc. 42: 266-269, 2010
  28. Brendan Clark, Neil Marsden, Katherine McKinley, Andrew Lewingtonand Chas Newstead Successful kidney transplantation with a well-matched donor despite a positive crossmatch; detection and management of sensitization secondary to an alternate allelic variant of ‘self’ HLA . Nephrology Dialysis Transplantation Plus 4: 258–259, 2011
  29. H. Zielinska, G. Moszkowska, M. Zielinski, A. Debska-Slizien , B. Rutkowski, and P. Trzonkowski: Algorithm to Manage Highly Sensitized Kidney Transplant Recipients in Poland. Transplant Proceed. 443:2903-2907, 20
  30. Alexandre Bosch, Santiago Llorente, Julio A. Diaz, Gema Salgado, Manuela LÔpez,Francisco Boix, Ruth LÔpez-HernÂndez, MarÎa J. GonzÂlez-Soriano, JosÊ A. Campillo,MarÎa R. Moya-Quilesa, Noelia Perez-Lopez, Alfredo Minguela, Luisa Jimeno,MarÎa R. A´lvarez-LÔpez, Manuel Muro: Low median fluorescence intensity could be a nonsafety concept of immunologicrisk evaluation in patients with shared molecular eplets in kidney transplantation. Human Immunol. 73:522-525, 2012
  31. Mierzejewska B, Schroder P, Caitlin, Baum C et al : Early acute antibody-mediated rejection of a negative flow crossmatch 3rd kidney transplant with exclusive disparity at HLA-DP Human Immunology 75:703-708, 2014
  32. Wiebe C, Nickerson P. Acceptable mismatching at the class II epitope level: the Canadian experience. Curr Opin Organ Transplant. 19:442–6, 2014.
  33. Filippone EJ, Farber JL. Humoral immunity in renal transplantation: epitopes, Cw and DP, and complement activating capability – an update. Clinical transplantation. 2015;29:279-287.
  34. Glotz D, Tambur A. Stratifying Patients Based on Epitope Mismatching: Ready for Primetime? (Editorial). Am J Transplant. 2015;15:2021-2022.
  35. Hwang SD, Lee MH, Chung BH, Kim Y, Han K, Yang CW, Oh E-J. Complement-binding donor epitope sharing antibodies in a kidney transplant recipient. Blood Transfusion 2015;13:161-163.
  36. Sapir-Pichhadze R, Tinckam K, Quach K, Logan AG, Laupacis A, John R, Beyene J, Kim SJ. HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study. Am J Transplant. 2015;15:137-148.
  37. Sullivan PM, Warner P, Kemna MS, Albers EL, Law SP, Weiss NS, Law YM. HLA molecular epitope mismatching and long-term graft loss in pediatric heart transplant recipients. The Journal of heart and lung transplantation : 2015;34:950-957.
  38. van Essen TH, Roelen DL, Williams KA, Jager MJ. Matching for Human Leukocyte Antigens (HLA) in corneal transplantation - to do or not to do. Progress in retinal and eye research. 2015;46:84-110.
  39. Visentin J, Guidicelli G, Moreau JF, Lee JH, Taupin JL. Deciphering allogeneic antibody response against native and denatured HLA epitopes in organ transplantation. Eur J Immunol. 2015;45:2111-2121.
  40. Wiebe C, Nevins TE, Robiner WN, Thomas W, Matas AJ, Nickerson PW. The Synergistic Effect of Class II HLA Epitope-Mismatch andNonadherence on Acute Rejection and Graft Survival. Am J Transplant. 2015;15:2197-2202.
  41. Bosch A, Eguia J, Boix F, Lopez M, Gonzalez-Martinez G, Galian JA, Moya-Quiles MR, Llorente S, Muro M. HLA Epitopes and Shared Molecular Eplet Characterization and Their Implication on Transplant Outcome: The Experience of One Center. Clinical transplants. 2016;32:73-82.
  42. Bryan CF, Chadha V, Warady BA. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm. Pediatric transplantation. 2016.
  43. Cai J, Terasaki PI, Zhu D, Lachmann N, Schonemann C, Everly MJ, Qing X. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection. Exp Mol Pathol. 2016;100:45-50.
  44. Chaigne B, Geneugelijk K, Bedat B, Ahmed MA, Honger G, de Seigneux S, Demuylder-Mischler S, Berney T, Spierings E, Ferrari- Lacraz S, Villard J. Immunogenicity of anti-HLA antibodies in pancreas and islet transplantation. Cell transplantation. 2016.
  45. Filippone EJ, Farber JL. The humoral theory of transplantation: Epitope analysis and the pathogenicity of HLA antibodies. J Immunol Res. 2016;10:12 .
  46. Kausman JY, Walker AM, Cantwell LS, Quinlan C, Sypek MP, Ierino FL. Application of an epitope-based allocation system in pediatric kidney transplantation. Pediatric transplantation. 2016.
  47. Kosmoliaptsis V, Mallon DH, Chen Y, Bolton EM, Bradley JA, Taylor CJ. Alloantibody Responses After Renal Transplant Failure Can Be Better Predicted by Donor-Recipient HLA Amino Acid Sequence and Physicochemical Disparities Than Conventional HLA Matching. Am J Transplant. 2016;16:2139-2147.
  48. Lachmann N, Schonemann C, El-Awar N, Everly M, Budde K, Terasaki PI, Waiser J. Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. Nephrol Dial Transplant. 2016;31:1351-1359.
  49. Milongo D, Kamar N, Del Bello A, Guilbeau-Frugier C, Sallusto F, Esposito L, Dörr G, Blancher A, Congy-Jolivet N. Allelic and epitopic characterization of intra-kidney-allograft anti-HLA antibodies at allograft nephrectomy. Am J Transplant. 2016;In press.
  50. Simmons DP, Kafetzi ML, Wood I, Macaskill PC, Milford EL, Guleria I. Antibodies against HLA-DP recognize broadly expressed epitopes. Hum Immunol. 2016.
  51. Singh P, Filippone EJ, Colombe BW, Shah AP, Zhan T, Harach M, Gorn C, Frank AM. Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized. Clinical transplantation. 2016;30:71-80. 37.
  52. Snanoudj R, Claas FH, Heidt S, Legendre C, Chatenoud L, Candon S. Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. Kidney Int. 2015;87:1230-1240.
  53. Tambur A. HLA-DQ antibodies: are they? Are they relevant? Why so many? Current opinion in organ transplantation. 2016;21:xx..
  54. Walton DC, Hiho SJ, Cantwell LS, Diviney MB, Wright ST, Snell GI, Paraskeva MA, Westall GP. HLA Matching at the Eplet Level Protects Against Chronic Lung Allograft Dysfunction. Am J Transplant. 2016;16:2695-2703.
  55. Wiebe C, Gareau AJ, Pochinco D, Gibson IW, Ho J, Birk PE, Blydt-Hasen T, Karpinski M, Goldberg A, Storsley L, Rush DN, Nickerson PW. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. Am J Transplant. 2016.
  56. Wiebe C, Nickerson P. Strategic Use of Epitope Matching to Improve Outcomes. Transplantation. 2016;100:2048-2052..
  57. Ferrari P, Cantwell L, Ta J, Woodroffe C, D'Orsogna L, Holdsworth R. Providing Better-Matched Donors for HLA Mismatched Compatible Pairs Through Kidney Paired Donation. Transplantation. 2017;101:642-648.
  58. Iwami D, Hotta K, Sasaki H, Hirose T, Higuchi H, Takada Y, Shinohara N. Highly Immunogenic DQB1 Mismatch Eplets Are Associated With Development of Chronic Active Antibody-Mediated Rejection: A First Report From Japan. Transplant Proc 2017;49:84-87.
  59. Jucaud V. The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA. J Immunol Res. 2017;2017:2748614.
  60. Pouliquen E, Baltzinger P, Lemle A, Chen CC, Parissiadis A, Borot S, Frimat L, Girerd S, Berney T, Lablanche S, Benhamou PY, Morelon E, Badet L, Dubois V, Kessler L, Thaunat O. Anti-Donor HLA Antibody Response After Pancreatic Islet Grafting: Characteristics, Risk Factors, and Impact on Graft Function. Am J Transplant. 2017;17:462-473.
  61. Sypek MP, Alexander SI, Cantwell L, Ierino FL, Ferrari P, Walker AM, Kausman JY. Optimizing Outcomes in Pediatric Renal Transplantation Through the Australian Paired Kidney Exchange Program. Am J Transplant. 2017;17:534-541.
  62. Sypek MP, Hughes P, Kausman JY. HLA epitope matching in pediatric renal transplantation. Pediatric nephrology (Berlin, Germany). 2017;32:1861-1869.
  63. Wekerle T, Segev D, Lechler R, Oberbauer R. Strategies for long-term preservation of kidney graft function. Lancet 2017;389:2152-2162.
  64. Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW, Goldberg A, Ho J, Karpinski M, Pochinco D, Sharma A, Storsley L, Matas AJ, Nickerson PW. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. J Am Soc Nephrol. 2017;28:3353-3362.
  65. Daniels L, Naesens M, Bosmans JL, Abramowicz D, Nagler E, Van Laecke S, Peeters P, Kuypers D, Emonds MP. The clinical significance of epitope mismatch load in kidney transplantation: A multicentre study. Transplant immunology. 2018;50:55-59.
  66. Fornera D, Liwski R, Alway N. Human leukocyte antigen, allele, and eplet mismatches in liver transplantation; observations from a small, single center cohort Hum Immunol. 2018;79:154-159.
  67. Kishikawa H, Kinoshita T, Hashimoto M, Fukae S, Taniguchi A, Yamanaka K, Nakagawa M, Nishimura K. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients. Transplant Proc 2018:2388-2391.
  68. Kubal CA, Mangus R, Ekser B, Mihaylov P, Ceballos B, Higgins N, Chalasani N, Ghabril M, Nephew L, Lobashevsky A. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation. Liver transplantation 2018;24:1101-1108.
  69. McCaughan JA, Battle RK, Singh SKS, Tikkanen JM, Moayedi Y, Ross HJ, Singer LG, Keshavjee S, Tinckam KJ. Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation. Am J Transplant. 2018;18:2924-2933.
  70. Meneghini M, Melilli E, Martorell J, Revuelta I, Rigol-Monzo E, Manonelles A, Montero N, Cucchiari D, Diekmann F, Cruzado JM, Gil-Vernet S, Grinyo JM, Bestard O. Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome. Kidney international reports. 2018;3:926-938.
  71. Rimando J, Slade M, DiPersio JF, Westervelt P, Gao F, Liu C, Romee R. HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. Blood advances. 2018;2:3590-3601.
  72. Sypek M, Kausman J, Holt S, Hughes P. HLA Epitope Matching in Kidney Transplantation: An Overview for the General Nephrologist. American jounal of kidney diseases : the official journal of the National Kidney Foundation. 2018;71:720-731.
  73. Thammanichanond D, Parapiboon W, Mongkolsuk T, Worawichawong S, Tammakorn C, Kitpoka P. Acute Antibody-Mediated Rejection by De Novo Anti-HLA-DPbeta and -DPalpha Antibodies After Kidney Transplantation: A Case Report. Transplantation proceedings. 2018;50:2548-2552.
  74. Walton DC, Cantwell L, Hiho S, Ta J, Wright S, Sullivan LC, Snell GI, Westall GP. HLA class II Eplet mismatch predicts De Novo DSA formation post lung transplant. Transpl Immunol 2018;51:73-75.
  75. Wiebe C, .Kosmoliaptsis V, Pochinco D, Gibson IW, Ho J, Birk PE, Goldberg A, Karpinski M, Shaw J, Rush DN, Nickerson PW. a HLA-DR/DQ Molecular Mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplant. 2018;Nov 10. doi: 10.1111/ajt.15177.
  76. Wiebe C, Kosmoliaptsis V, Pochinco D, Taylor C, Nickerson P. A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity. Transplantation. 2018;Volume Online First Issue
  77. Willicombe M, Blow M, Santos-Nunez E, Freeman C, Brookes P, Taube D. Terasaki Epitope Mismatch Burden Predicts the Development of De Novo DQ Donor-Specific Antibodies and are Associated With Adverse Allograft Outcomes. Transplantation. 2018;102:127-134.
  78. Argani H. Anti-HLA Antibody: The Role of Epitopes in Organ Transplantation. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2019;17:38-42.
  79. Delion A, Girerd S, Duarte K, Girerd N, Schikowski J, Kessler M, Frimat L, Aarnink A. Which is the best predictor of de novo donor-specific antibodies in a cohort of non-sensitized first kidney transplantation: Antigenic, allelic, epitope, or physiochemical HLA mismatches? Clinical transplantation. 2019;33:e13508.
  80. Ekong UD, Antala S, Bow L, Sese D, Morotti R, Rodriguez-Davalos M, Gan G, Deng Y, Emre SH. HLA, Non-HLA Antibodies, and Eplet Mismatches in Pediatric Liver Transplantation: Observations From a Small, Single-Center Cohort. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2019;17:6-17.
  81. Larkins NG, Wong G, Taverniti A, Lim WH. Epitope matching in kidney transplantation: recent advances and current limitations. Current opinion in organ transplantation. 2019;24:370-377.
  82. Guiral, S, San Segundo, D; Irure, J; Casafont, F; Fortea, José I; Puente, Á; López-Hoyos, M; Crespo, J; Fábrega, E: Number of antibidy-verified eplets in HLA-C locus as an independent factor of T cell mediated rejection after liver transplantation.Transplantation: August 8, 2019 doi: 10.1097/TP.0000000000002921

HLAMatchmaker Based Platelet Transfusion Reports

  1. Nambiar A, Duquesnoy RJ, Adams S, Zhao Y, Oblitas J, Leitman S, Stroncek D and Marincola F: HLAMatchmaker-Driven Analysis of Response To HLA Typed Platelet Transfusions In Alloimmunized Patients, Blood 107: 1690-1697, 2006
  2. Brooks EG, MacPherson BR and Fung MK: Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions. Transfusion 48: 2159-2165, 2008
  3. Pai SC, Lo SC, Lin Tsai SJ, Chang JS, Lin DT, Lin KS and Lin LI: Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion 50: 2318-2327, 2010
  4. Bub CB, Goncalez AC, Barjas-Castro ML, Sousa LC, do Monte SJ, Castro V. The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness. Vox sanguinis. 2016;110:70-78.
  5. O'Rafferty C, Rooney G, Hagan R, Woolfson M, O'Donghaile D, Fitzgerald J. HLAMatchmaker is effective for selecting appropriate platelet units for alloimmunised thrombocytopaenic patients who are refractory to random donor platelets. Transfusion medicine (Oxford, England). 2017;27 Suppl 5:369-374.
  6. Kallon D, Navarrete CV, Sage DA, Stanworth S, Mufti GJ, Marsh JCW, Brown CJ. Impact of Human Leucocyte Antigen epitope matched platelet transfusions in alloimmunised aplastic anaemia patients. Transfusion medicine (Oxford, England). 2019.
  7. Karlstrom C, Linjama T, Edgren G, Lauronen J, Wikman A, Hoglund P. HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience. Transfusion. 2019;59:945-952.
  8. Verduin EP, Schonewille H, Brand A, Haasnoot GW, Claas FHJ, Lindenburg ITM, et al. High anti-HLA response in women exposed to intrauterine transfusions for severe alloimmune hemolytic disease is associated with mother-child HLA triplet mismatches, high anti-D titer, and new red blood cell antibody formation. Transfusion. 2013;53(5):939-47.

Antibody Verification of Eplets, HLA Epitope Structure and Opinions, Etc

  1. Hulsmeyer M, Chames P, Hillig R, Stanfield R, Held G, Coulie P, et al. A Major Histocompatibility Complex-Peptide-restricted antibody and T Cell Receptor molecules recognize their Target by distinct binding modes. Crystal structure of Human Leukocyte Antigen (HLA)-A1 -MAGE-A1 complex with Fab-Hyb3 J Biol Chem. 2005;280:2972-80
  2. El-Awar N, Terasaki PI, Cai J, Deng CT, Ozawa M, Nguyen A, et al. Epitopes of the HLA-A, B, C, DR, DQ and MICA antigens. Clinical Transplants. 2007:175-94
  3. El-Awar N, Lee JH, Tarsitani C, Terasaki PI, El-Awar N, Lee J-H, et al. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Human Immunology. 2007;68(3):170-80.
  4. El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H, et al. Epitopes of HLA antibodies found in sera of normal healthy males and cord blood. Clinical Transplants. 2008:199-21.
  5. Dankers MK, Heemskerk MB, Duquesnoy RJ, Doxiadis II, Oudshoorn M, Roelen DL and Claas FH: HLAMatchmaker algorithm is not a suitable tool to predict the alloreactive cytotoxic T-lymphocyte response in vitro. Transplantation 78:165-7, 2004
  6. Kosmoliaptsis V, Bradley JA, Sharples LD, Chaudhry A, Key T, Goodman RS, et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation. 2008;85(12):1817-25.
  7. Kosmoliaptsis V, Chaudhry AN, Sharples LD, Halsall DJ, Dafforn TR, Bradley JA, et al. Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation. 2009;88(6):791-8.
  8. Tambur AR, Ching P, Ramon D. Prediction of immunogenic epitopes--is it feasible? Clinical Transplants. 2007:203-10
  9. El-Awar NR, Akaza T, Terasaki PI, Nguyen A. Human leukocyte antigen class I epitopes: update to 103 total epitopes, including the C locus. Transplantation. 2007;84(4):532-40. Maruya E, Sasaki N, El-Awar N, Akaza T, Kitawaki J, Saji H, et al. Immunogenic HLA class I epitopes identified by humoral response to pregnancies. Clinical Transplants. 2008:215- 27.
  10. Deng C-T, Cai J, Ozawa M, El- Awar N. HLA class II DP epitopes. Clinical Transplants. 2007:195-202
  11. Deng CT, El-Awar N, Ozawa M, Cai J, Lachmann N, Terasaki PI, et al. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation. 2008;86(3):452-9.
  12. Cai J, Terasaki PI, Cai J, Terasaki PI. Post-transplantation antibody monitoring and HLA antibody epitope identification. Current Opinion in Immunology. 2008;20(5):602-6.
  13. El-Awar N, Terasaki M, Cai J, Deng CT, Ozawa M, Lias M, et al. Epitopes of HLA-A, B, C, DR, DQ, DP and MICA Antigens. Clinical Transplants. 2009;2009:295-321.
  14. Kosmoliaptsis V, Sharples LD, Chaudhry AN, Halsall DJ, Bradley JA, Taylor CJ. Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation. 2011;91(2):183-90.
  15. Ravindranath MH, Taniguchi M, Chen CW, Ozawa M, Kaneku H, El-Awar N, et al. HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Molecular Immunology. 2010;47(5):1121-31
  16. El-Awar NR, Terasaki PI, Nguyen A, Lias M, Conger N. New HLA class I epitopes defined by murine monoclonal antibodies. Hum Immunol. 2010;71:456-61
  17. Tambur A, Leventhal JR, Friedewald J, Ramon D. The Complexity of Human Leukocyte Antigen (HLA)-DQ Antibodies and Its Effect on Virtual Crossmatching. Transplantation. 2010;90:1117- 24.
  18. Tambur A, Leventhal JR, Friedewald J and Ramon D: The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 90: 1117-11124, 2010
  19. Herton Luiz Alves Sales Filho, Luiz Claudio Demes da Mata Sousa, Cristina de Queiroz Carrascosa von Glehn, Adalberto Socorro da Silva,Pedro de Alcântara dos Santos Neto, Fernando Ferraz do Nascimento, José Adail Fonseca de Castro, Liliane Machado do Nascimento, Carolina Kneib, Helena Bianchi Cazarote, Daniele Mayumi Kitamura, Juliane Roberta Dias Torres,Laiane da Cruz Lopes, Lexlanna Aryela Loureiro Barros, Evelin Nildiane da Silva Edlin, Fernanda Sá Leal de Moura, Janine Midori Figueiredo Watanabe, Semiramis Jamil Hadad do Monte. EpHLA software: A timesaving and accurate tool for improving identification of acceptable mismatches for clinical purposes. Transplant Immunology 26: 230-234, 2012
  20. Tambur AR, Leventhal JR, Zitzner JR, Walsh RC, Friedewald JJ. The DQ barrier: improving organ allocation equity using HLA-DQ information. Transplantation. 2013;95(4):635-40.
  21. Cano P, Fernandez-Vina M (2009) Two sequence dimorphisms of DPB1 define the immunologically serologic epitopes. Hum Imm 70:836- 843, 2009
  22. Zou Y, Qin Z, Silveus A, Fan Y, Stastny P. Polymorphisms of MICA recognized by human alloantibodies. Immunogenetics. 2009;61(2):91-100.
  23. Suarez-Alvarez B, Alonso-Arias R, Bravo-Mendoza C, Lopez- Vazquez A, Ortega T, Baltar JM, et al. Identification of epitopes and immunodominant regions on the MICA protein defined by alloantibodies from kidney transplant patients. Transplantation. 2009;88(3 Suppl):S68-77.
  24. Kosmoliaptsis V, Sharples LD, Chaudhry A, Johnson RJ, Fuggle SV, Halsall DJ, et al. HLA class I amino acid sequence-based matching after interlocus subtraction and long-term outcome after deceased donor kidney transplantation. Human Immunology. 2010;71(9):851-6.
  25. Ravindranath MH, Pham T, El- Awar N, Kaneku H, Terasaki PI. Anti-HLA-E mAb 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: Web-tools validate the immunogenic epitopes of HLA-E recognized by the antibodies. Molecular Immunology. 2011;48(4):423- 30
  26. Sousa LCDM, Sales HLA, Von Glehn C, Silva AS, Santos Neto PA, Castro JAF, et al. EpHLA: An innovative and user-friendly software automating the HLAMatchmaker algorithm for antibody analysis. Transplant Immunol. 2011;25:210-6.
  27. Kosmoliaptsis V, Dafforn TR, Chaudhry AN, Halsall DJ, Bradley JA, Taylor CJ. High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Human Immunology. 2011;72(11):1049-59.
  28. Carly J. Callender Marcelo Fernandez-Vina M,ary S. Leffell, Andrea A. Zachary:Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group. Hum Immunol 73:175-179, 2012
  29. Resse M, Paolillo R, Casamassimi A, Cavalca F, Fiorito C, Maiello C, et al. Anti- HLA-A, -B, -DR, -DQB1 and - DQA1 antibodies reactive epitope determination with HLAMatchmaker in multipare awaiting list for heart transplant. Hum Immunol. 2013;74:937–41.
  30. Hollenbach JA, Madbouly A, Gragert L, Vierra-Green C, Flesch S, Spellman S, et al. A combined DPA1~DPB1 amino acid epitope is the primary unit of selection on the HLA-DP heterodimer. Immunogenetics. 2012;64(8):559-69.
  31. El-Awar N, Nguyen A, Almeshari K, Alawami M, Alzayer F, Alharbi M, et al. HLA class II DQA and DQB epitopes: Recognition of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines. Human Immunology. 2013;74:1141-52.
  32. Wiebe C, Pochinco D, Blydt- Hansen TD, et al Class II HLA Epitope Matching—A Strategy to Minimize De Novo Donor- Specific Antibody Development and Improve Outcomes. Am J Transplant. 2013;13:3114–22.
  33. Lutz CT, Al-Attar A, May JR, Jennings CD. Alloantibody to a Bw4 Epitope in a Bw4+ B*27:05 Patient. Transplantation. 2014xxx
  34. Tambur A, Rosati J, Roitberg R, Glotz D, Friedewald JJ, Leventhal JR. Epitope analysis of HLA-DQ antigens: what does the antibody see? Transplantation. 2014;98:157- 66.
  35. Lutz CT: Human leukocyte antigen Bw4 and Bw6 epitopes recognized by antibodies and natural killer cells. Curr Opin Organ Transplant 19:436-441, 2014
  36. Mallon D, Kosmoliaptsis V, Peacock S, Bradley JA, Taylor CJ. Structural and electrostatic analysis of HLA B-cell epitopes: Inference on immunogenicity and prediction of humoral alloresponses. Curr Opin Organ Transplant. 19:420–7, 2014
  37. Mallon DH, Bradley JA, Winn PJ, Taylor CJ, Kosmoliaptsis V: Three-Dimensional Structural Modelling and Calculation of Electrostatic Potentials of HLA Bw4 and Bw6 Epitopes to Explain the Molecular Basis for Alloantibody Binding: Toward Predicting HLA Antigenicity and Immunogenicity Transplantation 99:385-390, 2015
  38. Resse M, Paolillo R, Minucci BP, Cavalca F, Casamassimi A, Napoli C. Epitope-specificities of HLA antibodies: the effect of epitope structure on Luminex technique-dependent antibody reactivity. Hum Immunol. 2015;76:297-300.
  39. Resse M, Paolillo R, Minucci BP, Moccia G, Napoli C. Antibody-reactive class I epitopes defined by pairs of mismatched eplets and self-eplets. Tissue antigens. 2015;86:368-372.
  40. Hahn AB, Bravo-Egana V, Jackstadt JL, Conti DJ and R.J.Duquesnoy: HLA-A2 reactive antibodies in a patient who types as HLA-A2: The importance of high resolution typing and epitope-based antibody analysis, Transplant Immunol 32:141-143, 2015
  41. Anunciacao FA, Sousa LC, da Silva AS, Marroquim MS, Coelho AG, Willcox GH, de Andrade JM, Correa B de M, Guimaraes EL, do Monte SJ. EpViX: A cloud-based tool for epitope reactivity analysis and epitope virtual crossmatching to identify low immunologic risk donors for sensitized recipients. Transplant immunology. 2015;33:153-158.
  42. Snanoudj R, Claas FH, Heidt S, Legendre C, Chatenoud L, Candon S. Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. Kidney Int. 2015; 87:1230-1240.
  43. Tambur AR, Claas FH: HLA Epitopes as Viewed by Antibodies: What Is it All About? Amer J Transplant 32:141-143, 2015.
  44. El-Awar N, Jucaud V, Nguyen A: HLA epitopes: The targets of monoclonal and alloantibodies defined. J Immunol Research 2017 https://doi.org/10.1155/2017/3406230
  45. Yue G, Yee HW, Chong WL, Conrad E.Z, T M. Murali, J Yap, Chien Tei Too, K Purushotorman,M Hamidinia, AE, Sahili, A T.H. Goh, RZ.C. Teo, K J. Wood, BJ. Hanson, NR.J. Gascoigne, Julien Lescar, A Vathsala, & P A. MacAry, Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-A*11:01 Nature Communications 2019 https://doi.org/0.1038/s4146- 019-0890-1
  46. D'Souza Y, Ferradji A, Saw C, Oualkacha K, Richard L, Popradi G, Sapir-Pichhadze R: Inaccuracies in epitope repertoire estimations when using Multi-Locus Allele-Level HLA genotype imputation tools. HLA. 2018 Jun 10. doi: 10.1111/tan.13307.